Want to see ABBV full AI Analyst Report?
ABBV Stock Chart & Stats
$208.38
-$1.97(-1.10%)
At close: 4:00 PM EST
$208.38
-$1.97(-1.10%)
Day’s Range― - ―
52-Week Range$181.73 - $244.81
Previous CloseN/A
Volume1.02M
Average Volume (3M)5.53M
Market Cap
$444.60B
Enterprise Value$454.33B
Total Cash (Recent Filing)$9.39B
Total Debt (Recent Filing)$72.86B
Price to Earnings (P/E)123.3
Beta0.11
Next Earnings
Jul 31, 2026EPS Estimate
3.76Next Dividend Ex-DateN/A
Dividend Yield2.87%
Share Statistics
EPS (TTM)2.04
Shares Outstanding1,766,792,800
10 Day Avg. Volume5,463,388
30 Day Avg. Volume5,532,482
Financial Highlights & Ratios
PEG Ratio-77.13
Price to Book (P/B)-124.40
Price to Sales (P/S)6.65
P/FCF Ratio22.83
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue7.23
Enterprise Value/Gross Profit10.23
Enterprise Value/Ebitda26.85
Forecast
1Y Price Target
$258.28Price Target Upside23.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering21
EPS Forecast (FY)14.23
Revenue Forecast (FY)$67.32B
Bulls Say, Bears Say
Bulls Say
Free Cash Flow GenerationSustained, large FCF (TTM ~$20.9B) provides durable funding for R&D, capital investment, M&A and dividends. Over multiple quarters this strong cash conversion underpins strategic flexibility to invest in growth and manage leverage without relying on equity markets.
Immunology Commercial MomentumRapid, repeatable growth from Skyrizi and Rinvoq reflects a structural shift in the portfolio toward high-growth immunology franchises. Durable adoption across indications supports long-term revenue replacement for legacy Humira and strengthens AbbVie’s sustained market position in immunology.
Strategic Pipeline Expansion (Apogee Deal)The Apogee acquisition meaningfully deepens late‑stage immunology and respiratory assets, widening biologics pipeline and dosing advantages. As a structural BD move, it complements internal R&D and supports long‑term franchise renewal and category leadership beyond Humira decline.
Bears Say
High Leverage / Weak Capital StructureVery large absolute debt and negative/volatile equity materially reduce balance-sheet resilience. Over months to years this increases refinancing and interest-rate vulnerability, limits ability to absorb earnings shocks, and constrains capital allocation until leverage is meaningfully reduced.
HUMIRA Biosimilar ErosionSharp, structural decline in Humira revenue is an enduring headwind that removes a historic cash engine. Replacing that scale demands sustained success of newer brands and pipeline approvals; any shortfall prolongs revenue pressure and complicates deleveraging plans.
Compressed Net Margins Versus Prior PeakMaterial decline in net margin reflects higher non‑operating costs, IPR&D and financing impacts that persistently erode bottom‑line durability. Sustained margin compression reduces retained earnings to pay down debt and fund growth, raising execution risk on strategic investments.
AbbVie News
ABBV FAQ
What was Abbvie’s price range in the past 12 months?
Abbvie lowest stock price was $181.73 and its highest was $244.81 in the past 12 months.
What is Abbvie’s market cap?
Abbvie’s market cap is $444.60B.
When is Abbvie’s upcoming earnings report date?
Abbvie’s upcoming earnings report date is Jul 31, 2026 which is in 29 days.
How were Abbvie’s earnings last quarter?
Abbvie released its earnings results on Apr 29, 2026. The company reported $2.65 earnings per share for the quarter, beating the consensus estimate of $2.592 by $0.058.
Is Abbvie overvalued?
According to Wall Street analysts Abbvie’s price is currently Undervalued.
Does Abbvie pay dividends?
Abbvie pays a Quarterly dividend of $1.73 which represents an annual dividend yield of 2.87%. See more information on Abbvie dividends here
What is Abbvie’s EPS estimate?
Abbvie’s EPS estimate is 3.76.
How many shares outstanding does Abbvie have?
Abbvie has 1,766,792,800 shares outstanding.
What happened to Abbvie’s price movement after its last earnings report?
Abbvie reported an EPS of $2.65 in its last earnings report, beating expectations of $2.592. Following the earnings report the stock price went up 3.136%.
Which hedge fund is a major shareholder of Abbvie?
Currently, no hedge funds are holding shares in ABBV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AbbVie Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$258.28 (23.95% Upside)
$258.28 (23.95% Upside)
Blogger Sentiment
Bullish
ABBV Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 8.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.7%
Last 30 Days ▲ 6.1%
Last 30 Days ▲ 6.1%
News Sentiment
Very Bullish
Bullish news 93%
Bearish news 7%
Bearish news 7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.98%
12-Months-Change
Fundamentals
Return on Equity
68.01%
Trailing 12-Months
Asset Growth
0.22%
Trailing 12-Months
Company Description
Abbvie
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
ABBV Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and financial performance with multiple product growth drivers (Skyrizi, Rinvoq, neuroscience portfolio) and a raised full-year outlook. Substantial pipeline progress (regulatory submissions, combination Crohn's data, obesity signal) and major manufacturing investments reinforce long-term growth positioning. Offsets include expected HUMIRA biosimilar erosion, pressure in some oncology and aesthetic segments, selected clinical setbacks/non-differentiation and near-term acquired IPR&D expense impacts. On balance, highlights — including robust sales beats, double-digit growth for key franchises, guidance raise, and encouraging pipeline readouts — outweigh the lowlights.View all ABBV earnings summariesABBV Net revenue Breakdown
47.36% Immunology
15.97% Neuroscience
11.86% Other Key Products
11.64% Oncology
13.17% Other
ABBV Stock 12 Month Forecast
Average Price Target
$258.28
▲(23.95% Upside)
Technical Analysis
Ownership Overview
0.06% Insiders
20.81% Mutual Funds
14.65% Other Institutional Investors
41.15% Public Companies and Individual Investors